Clinical Trials Logo

Purpura clinical trials

View clinical trials related to Purpura.

Filter by:

NCT ID: NCT02877212 Recruiting - Clinical trials for Immune Thrombocytopenic Purpura (ITP)

Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients

Start date: July 2016
Phase: Phase 3
Study type: Interventional

Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease characterized by antibody-mediated platelet destruction. The complex pathogenesis of ITP with multiple challenges to immune system in terms of genetic predisposition, infection, responsiveness to immunosuppressive therapy (IST) and inhibition of platelet production has proven the diversity of constraints in diagnosing and treating ITP. Thrombopoietin receptor agonist (Eltrombopag) is specifically indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. This clinical trial aims to investigate the association of Fc gammaRIIIA gene (V158F) genetic predisposition with treatment outcome of Immune Thrombocytopenia (ITP) in refractory ITP patients and especially with Eltrombopag.

NCT ID: NCT02854059 Terminated - Clinical trials for Purpura, Thrombotic Thrombocytopenic

IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients

Start date: September 2016
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate safety and tolerability in patients diagnosed with asymptomatic antibody-mediated TTP with low ADAMTS13 activity after receiving single intravenous dose of IdeS.

NCT ID: NCT02626663 Withdrawn - Clinical trials for Thrombotic Thrombocytopenic Purpura

The Role of Microparticles as a Biomarker

Start date: July 2016
Phase:
Study type: Observational

The investigators propose to characterize MPs in aHUS and TTP both at the onset and throughout treatment. The investigators believe that the number, size, and cell origin of MPs will differ between these two diseases. The hypothesis is that endothelial derived MPs will be higher in number and comprise a larger portion of the MP population in aHUS and that platelet MPs will comprise a larger number and greater proportion of MPs in TTP. The investigators believe that MP identity and number can be used to reliably differentiate between aHUS and TTP at disease onset.

NCT ID: NCT02614846 Recruiting - Clinical trials for Chronic Idiopathic Thrombocytopenic Purpura

Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

Start date: August 2015
Phase: Phase 1
Study type: Interventional

This study evaluates the safety and efficacy of 6 weeks dosing Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura Patients. All of the subjects in this study receive Hetrombopag.

NCT ID: NCT02593565 Recruiting - Vasculitis Clinical Trials

Vasculitis Pregnancy Registry

V-PREG
Start date: November 2015
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to learn about the experience of women with vasculitis who become pregnant. In particular, the study will consist of several online surveys to assess 1. each woman's vasculitis severity and pregnancy-related experiences, and 2. pregnancy outcomes.

NCT ID: NCT02553317 Completed - Clinical trials for Acquired Thrombotic Thrombocytopenic Purpura

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

HERCULES
Start date: November 2015
Phase: Phase 3
Study type: Interventional

The study was a Phase III, double-blind, placebo-controlled, randomized study to evaluate the efficacy of caplacizumab in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis

NCT ID: NCT02540720 Recruiting - Clinical trials for Henoch-Schoenlein Purpura

The Research of Standard Diagnosis and Treatment for Severe HSP in Children

Start date: August 2015
Phase: Phase 2
Study type: Interventional

This study is performed to evaluate the efficacy and safety of various measures in the treatment of severe HSP in children.

NCT ID: NCT02532790 Recruiting - Clinical trials for Henoch-Schoenlein Purpura Nephritis

The Research of Standard Diagnosis and Treatment for HSPN With Mild Proteinuria in Children

Start date: August 2015
Phase: Phase 2
Study type: Interventional

This study is performed to evaluate the efficacy and safety of various measures in the treatment of HSPN with mild proteinuria in children.

NCT ID: NCT02532777 Recruiting - Clinical trials for Henoch-Schoenlein Purpura Nephritis

The Research of Standard Diagnosis and Treatment for HSPN in Children

Start date: August 2015
Phase: Phase 2
Study type: Interventional

This study is performed to evaluate the efficacy and safety of various measures in the treatment of HSPN in children.

NCT ID: NCT02403440 Recruiting - Clinical trials for Purpura, Thrombocytopenic, Idiopathic

A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

Start date: April 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to obtain information on efficacy, safety and Pharmacokinetics (PK)/Pharmacodynamics (PD) of Hetrombopag over 14 days in Chinese patients with chronic ITP.